{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:04:41Z","timestamp":1785542681033,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"DOI":"10.7759\/cureus.113743","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T21:05:52Z","timestamp":1785531952000},"source":"Crossref","is-referenced-by-count":0,"title":["Synchronous Clear Cell and Papillary Renal Cell Carcinoma Collision Tumor Confirmed by Component-Specific Next-Generation Sequencing: A Case Report"],"prefix":"10.7759","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina X","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","unstructured":"Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013, 499.43-49. 10.1038\/nature12222","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh JJ","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, et al.. Renal cell carcinoma. Nat Rev Dis Primers. 2017, 3:17009. 10.1038\/nrdp.2017.9","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.03.075","article-title":"The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","author":"Ricketts CJ","year":"2018","unstructured":"Ricketts CJ, De Cubas AA, Fan H, et al.. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018, 23:313-326.e5. 10.1016\/j.celrep.2018.03.075","journal-title":"Cell Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0329000","article-title":"Renal cancer survival in clear cell renal cancer compared to other types of tumor histology: a population-based cohort study","volume":"20","author":"Sepp T","year":"2025","unstructured":"Sepp T, Poyhonen A, Uusk\u00fcla A, et al.. Renal cancer survival in clear cell renal cancer compared to other types of tumor histology: a population-based cohort study. PLoS One. 2025, 20:e0329000. 10.1371\/journal.pone.0329000","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2024.02.005","article-title":"Actual encounters of the kidney kind: exploring 48 cases of renal collision tumors through the lens of literature","volume":"145","author":"Lerma LA","year":"2024","unstructured":"Lerma LA, Pease G, Malleis J, Antic T, Hes O, Tretiakova M. Actual encounters of the kidney kind: exploring 48 cases of renal collision tumors through the lens of literature. Hum Pathol. 2024, 145:26-33. 10.1016\/j.humpath.2024.02.005","journal-title":"Hum Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.10.013","article-title":"Multiple discordant histology after nephrectomy: descriptive analysis and outcomes","volume":"14","author":"Harlow BL","year":"2016","unstructured":"Harlow BL, Klaassen Z, Holzman S, et al.. Multiple discordant histology after nephrectomy: descriptive analysis and outcomes. Clin Genitourin Cancer. 2016, 14:e171-e175. 10.1016\/j.clgc.2015.10.013","journal-title":"Clin Genitourin Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-024-03820-w","article-title":"Shared chromosome 21q loss in a mixed subtype renal cell carcinoma: composite or collision tumor?","volume":"486","author":"Stephen SA","year":"2025","unstructured":"Stephen SA, Wainman LM, Lefferts JA, Pettus JR. Shared chromosome 21q loss in a mixed subtype renal cell carcinoma: composite or collision tumor?. Virchows Arch. 2025, 486:1079-1083. 10.1007\/s00428-024-03820-w","journal-title":"Virchows Arch"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000042312","article-title":"Occurrence of papillary renal cell carcinoma and clear cell renal carcinoma in a patient: a unique case report","volume":"104","author":"Harizanova Z","year":"2025","unstructured":"Harizanova Z, Popova F, Pavlov V, Bozhikova E. Occurrence of papillary renal cell carcinoma and clear cell renal carcinoma in a patient: a unique case report. Medicine (Baltimore). 2025, 104:e42312. 10.1097\/MD.0000000000042312","journal-title":"Medicine (Baltimore)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/575181","article-title":"Coexisting papillary and clear renal cell carcinoma in the same kidney","volume":"2014","author":"Ustuner M","year":"2014","unstructured":"Ustuner M, Yaprak B, Teke K, Ciftci S, Kart M, Yildiz K, Culha M. Coexisting papillary and clear renal cell carcinoma in the same kidney. Case Rep Urol. 2014, 2014:575181. 10.1155\/2014\/575181","journal-title":"Case Rep Urol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00659-1","article-title":"PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma","volume":"20","author":"Walton J","year":"2023","unstructured":"Walton J, Lawson K, Prinos P, Finelli A, Arrowsmith C, Ailles L. PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma. Nat Rev Urol. 2023, 20:96-115. 10.1038\/s41585-022-00659-1","journal-title":"Nat Rev Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.204","article-title":"Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile","volume":"26","author":"Williamson SR","year":"2013","unstructured":"Williamson SR, Eble JN, Cheng L, Grignon DJ. Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile. Mod Pathol. 2013, 26:697-708. 10.1038\/modpathol.2012.204","journal-title":"Mod Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5527\/wjn.v7.i8.155","article-title":"Clear cell papillary renal cell carcinoma: a case report and review of the literature","volume":"7","author":"Kim SH","year":"2018","unstructured":"Kim SH, Kwon WA, Joung JY, Seo HK, Lee KH, Chung J. Clear cell papillary renal cell carcinoma: a case report and review of the literature. World J Nephrol. 2018, 7:155-160. 10.5527\/wjn.v7.i8.155","journal-title":"World J Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1284194","article-title":"Case report: A collision tumor of clear cell renal cell carcinoma and clear cell papillary renal cell tumor","volume":"14","author":"Lin Y","year":"2024","unstructured":"Lin Y, Guo J, Li Z, et al.. Case report: A collision tumor of clear cell renal cell carcinoma and clear cell papillary renal cell tumor. Front Oncol. 2024, 14:1284194. 10.3389\/fonc.2024.1284194","journal-title":"Front Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4963","article-title":"Point mutations of the mTOR-RHEB pathway in renal cell carcinoma","volume":"6","author":"Ghosh AP","year":"2015","unstructured":"Ghosh AP, Marshall CB, Coric T, et al.. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma. Oncotarget. 2015, 6:17895-17910. 10.18632\/oncotarget.4963","journal-title":"Oncotarget"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-024-01476-3","article-title":"A rare case of TFEB\/6p21\/VEGFA-amplified renal cell carcinoma diagnosed by whole-exome sequencing: clinicopathological and genetic feature report and literature review","volume":"19","author":"Zhang R","year":"2024","unstructured":"Zhang R, Ding M, Zhu X, et al.. A rare case of TFEB\/6p21\/VEGFA-amplified renal cell carcinoma diagnosed by whole-exome sequencing: clinicopathological and genetic feature report and literature review. Diagn Pathol. 2024, 19:66. 10.1186\/s13000-024-01476-3","journal-title":"Diagn Pathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1829","article-title":"TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas","volume":"5","author":"Wang K","year":"2014","unstructured":"Wang K, Liu T, Liu L, et al.. TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas. Oncotarget. 2014, 5:1829-1836. 10.18632\/oncotarget.1829","journal-title":"Oncotarget"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155774","article-title":"Tumor infiltrating T-cells and loss of expression of SWI\/SNF genes in varying stages of clear cell renal cell carcinoma","volume":"266","author":"Hrizat AS","year":"2025","unstructured":"Hrizat AS, Lin R, Eberle-Singh J, et al.. Tumor infiltrating T-cells and loss of expression of SWI\/SNF genes in varying stages of clear cell renal cell carcinoma. Pathol Res Pract. 2025, 266:155774. 10.1016\/j.prp.2024.155774","journal-title":"Pathol Res Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70584-3","article-title":"Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation","volume":"14","author":"Kapur P","year":"2013","unstructured":"Kapur P, Pe\u00f1a-Llopis S, Christie A, et al.. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 2013, 14:159-167. 10.1016\/S1470-2045(12)70584-3","journal-title":"Lancet Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao D","year":"2018","unstructured":"Miao D, Margolis CA, Gao W, et al.. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018, 359:801-806. 10.1126\/science.aan5951","journal-title":"Science"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al.. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020, 21:1353-1365. 10.1016\/S1470-2045(20)30445-9","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/516662-synchronous-clear-cell-and-papillary-renal-cell-carcinoma-collision-tumor-confirmed-by-component-specific-next-generation-sequencing-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T21:05:53Z","timestamp":1785531953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/516662-synchronous-clear-cell-and-papillary-renal-cell-carcinoma-collision-tumor-confirmed-by-component-specific-next-generation-sequencing-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.113743","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,31]]}}}